Displaying items by tag: center for neurodegeneration and experimental therapeutics

TCE is a known environmental risk factor for parkinsonism. UAB researchers will evaluate whether T cell activation caused by TCE exposure leads to cognitive decline.
In a mouse model, border-associated macrophages, not microglia, were essential for the neuroinflammation that precedes neurodegradation. Targeting this subset could be a disease-modifying therapy in neurodegenerative disease.
Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.
Tagged under
New results suggest the answer is no, implying that the role of tau in the pathogenesis of Lewy body dementias is distinct from Alzheimer’s disease.
The University of Alabama at Birmingham’s Dr. Michelle Gray has been elected to be a member on the Scientific Board of the Hereditary Disease Foundation.
Researchers have found that an interaction between a mutant gene and alpha synuclein in neurons leads to hallmark pathologies seen in Parkinson’s disease, findings that may lead to new mechanisms and targets for neuroprotection.
An intriguing paper by Harvard researchers has everyone talking, thanks to widespread media coverage. Neuroscientist Erik Roberson, M.D., Ph.D., co-director of UAB's Center for Neurodegeneration and Experimental Therapeutics, offers his thoughts on a discovery gone viral.